Pethema Foundation

This study tests a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) in 62 adults with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in cancer. Because …

This study tests two drug combinations—iberdomide plus dexamethasone, with or without daratumumab—in 140 older adults (65+) newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well these treatments control the cancer and h…

This study tests a new combination of three drugs (belantamab mafodotin, carfilzomib, and dexamethasone) in people whose multiple myeloma has come back and no longer responds to lenalidomide. The goal is to find the safest dose and see how well the combo controls the cancer. Abou…

This study tests two new drug combinations (teclistamab plus daratumumab and talquetamab plus daratumumab) as early treatment for people newly diagnosed with a high-risk form of multiple myeloma, a blood cancer. The goal is to see if these treatments can make the cancer disappear…

This study tests a drug called elranatamab in 50 adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The goal is to see if the drug can make cancer undetectable in the bone marrow at 6 and 12 months. Researchers will also monit…

This study tests a new drug, belantamab mafodotin, combined with standard therapy (VRd) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and effective. Patients receive several cycles of …